Branchburg, NJ (PRWEB) March 13, 2011
ZEUS Scientific announced it has received clearance from the U.S. Food and Drug Administration (FDA) to market the ZEUS ELISA Treponema pallidum IgG Test System. This new Test System is intended for the qualitative detection of specific human IgG class antibodies to Treponema pallidum in human sera. The presence of antibodies to Treponema pallidum specific antigen, in conjunction with non-treponemal laboratory tests and clinical findings, may aid in the diagnosis of syphilis infection.
Syphilis is a bacterial infection that is usually sexually transmitted, but may also be passed from an infected mother to her unborn child. Syphilis is a curable sexually transmitted disease (STD) which, if left untreated, can eventually lead to irreversible damage to the heart and nervous system. Syphilis remains a global problem with an estimated 12 million people infected each year, despite the existence of effective prevention measures.
In conjunction with the recently cleared AtheNA Multi-Lyte® Treponema pallidum IgG Plus Test System, ZEUS Scientific now offers the clinical market multiple testing solutions for the qualitative detection of specific human IgG class antibodies to Treponema pallidum in human sera.
Both the ZEUS ELISA Treponema pallidum IgG Test System and the AtheNA Multi-Lyte® Treponema pallidum IgG Plus Test System are available for sale through the global ZEUS Scientific distribution network. Please visit http://www.zeusscientific.com to locate your local distributor.